Repligen Corp SEC filings RGEN
Repligen Corp has 1,003 filings in SEC EDGAR's recent list, going back to May 13, 2010. Its latest annual report, Form ARS, was filed on Apr 2, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 30, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (unregistered share sale, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 27, 2026 | — |
| DEFA14A | Additional proxy material | Apr 2, 2026 | — |
| DEF 14A | Proxy statement | Apr 2, 2026 | May 14, 2026 |
| DEFA14A | Additional proxy material | Apr 4, 2025 | — |
| DEF 14A | Proxy statement | Apr 4, 2025 | Apr 3, 2025 |
| PRE 14A | Preliminary proxy statement | Mar 17, 2025 | Mar 17, 2025 |
| DEFA14A | Additional proxy material | May 3, 2024 | — |
| DEFA14A | Additional proxy material | Apr 1, 2024 | — |
| DEF 14A | Proxy statement | Apr 1, 2024 | May 16, 2024 |
| DEF 14A | Proxy statement | Apr 11, 2023 | — |
| PRE 14A | Preliminary proxy statement | Mar 24, 2023 | — |
| DEFA14A | Additional proxy material | Apr 11, 2022 | — |
| DEF 14A | Proxy statement | Apr 11, 2022 | May 26, 2022 |
| DEF 14A | Proxy statement | Apr 21, 2021 | May 13, 2021 |
| DEF 14A | Proxy statement | Apr 28, 2020 | May 13, 2020 |
| DEF 14A | Proxy statement | Apr 18, 2019 | May 15, 2019 |
| DEFA14A | Additional proxy material | May 3, 2018 | — |
| DEF 14A | Proxy statement | Apr 20, 2018 | May 16, 2018 |
| DEF 14A | Proxy statement | Apr 21, 2017 | May 18, 2017 |
| PRE 14A | Preliminary proxy statement | Apr 7, 2017 | May 18, 2017 |
| DEF 14A | Proxy statement | Apr 11, 2016 | May 11, 2016 |
| DEF 14A | Proxy statement | Apr 17, 2015 | May 21, 2015 |
| DEF 14A | Proxy statement | Apr 8, 2014 | May 15, 2014 |
| PRE 14A | Preliminary proxy statement | Mar 21, 2014 | May 15, 2014 |
| DEF 14A | Proxy statement | Apr 9, 2013 | May 9, 2013 |
| DEFA14A | Additional proxy material | May 7, 2012 | — |
| DEF 14A | Proxy statement | Apr 20, 2012 | May 24, 2012 |
| DEF 14A | Proxy statement | Jul 29, 2011 | Sep 27, 2011 |
| DEF 14A | Proxy statement | Jul 28, 2010 | Sep 9, 2010 |
Showing 29 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- RGEN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 730272
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.